LSB vs. DMAC, ZURA, CGEN, BIVI, MDWD, ACTU, VXRT, GBIO, FTLF, and PRQR
Should you be buying Lakeshore Biopharma stock or one of its competitors? The main competitors of Lakeshore Biopharma include DiaMedica Therapeutics (DMAC), Zura Bio (ZURA), Compugen (CGEN), BioVie (BIVI), MediWound (MDWD), Actuate Therapeutics (ACTU), Vaxart (VXRT), Generation Bio (GBIO), FitLife Brands (FTLF), and ProQR Therapeutics (PRQR). These companies are all part of the "pharmaceutical products" industry.
DiaMedica Therapeutics (NASDAQ:DMAC) and Lakeshore Biopharma (NASDAQ:LSB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, community ranking, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.
DiaMedica Therapeutics has a beta of 1.47, meaning that its share price is 47% more volatile than the S&P 500. Comparatively, Lakeshore Biopharma has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500.
DiaMedica Therapeutics presently has a consensus target price of $7.00, suggesting a potential upside of 73.70%. Given DiaMedica Therapeutics' higher possible upside, equities analysts clearly believe DiaMedica Therapeutics is more favorable than Lakeshore Biopharma.
In the previous week, Lakeshore Biopharma had 1 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 2 mentions for Lakeshore Biopharma and 1 mentions for DiaMedica Therapeutics. DiaMedica Therapeutics' average media sentiment score of 0.00 equaled Lakeshore Biopharma'saverage media sentiment score.
DiaMedica Therapeutics has higher earnings, but lower revenue than Lakeshore Biopharma.
10.1% of DiaMedica Therapeutics shares are owned by institutional investors. Comparatively, 52.6% of Lakeshore Biopharma shares are owned by institutional investors. 7.2% of DiaMedica Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Lakeshore Biopharma's return on equity of 0.00% beat DiaMedica Therapeutics' return on equity.
DiaMedica Therapeutics received 91 more outperform votes than Lakeshore Biopharma when rated by MarketBeat users.
Summary
DiaMedica Therapeutics beats Lakeshore Biopharma on 6 of the 11 factors compared between the two stocks.
Get Lakeshore Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for LSB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LSB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Lakeshore Biopharma Competitors List
Related Companies and Tools